Sierra Oncology’s $103 Million Public Offering of Convertible Preferred Stock and Warrants

Fenwick & West represented Sierra Oncology, Inc. in the deal.

Sierra Oncology, Inc. (NASDAQ: SRRA) issued its underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with gross proceeds to Sierra Oncology of $103 million.

Jefferies acted as the sole book-running manager for the offering. Oppenheimer & Co. acted as lead manager for the offering.

Sierra Oncology, Inc. is a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis.

The Fenwick transaction team was led by corporate partners Robert Freedman (Picture), Stephen Graham and Amanda Rose, associates Ryan Mitteness, Alice Lin, Chelsea Anderson, Derrick Chapman and John Clancy; and intellectual property partner Daniel Becker and associate Andrea Nichols.

Involved fees earner: Chelsea Anderson – Fenwick & West LLP; Daniel Becker – Fenwick & West LLP; Derrick Chapman – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Stephen Graham – Fenwick & West LLP; Alice Lin – Fenwick & West LLP; Ryan Mitteness – Fenwick & West LLP; Andrea Nichols – Fenwick & West LLP; Amanda Rose – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Sierra Oncology, Inc.;

Author: Ambrogio Visconti